VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Vericel Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026

$40.37+0.24 (+0.60%)

Close on Oct 19, 2026

Market cap: $2.11B
P/E (TTM): 96.1
Dividend yield: –

Vericel Corp cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2010 2010-06-30	FY 2009 2009-06-30
Depreciation & Amortization	12	5.50	4.63	3.98	2.97	2.38	1.70	1.43	1.61	1.89	1.59	0.75	0.49	0.65	0.59	0.70
Stock-Based Compensation	39	36	32	37	34	14	13	7.22	2.68	2.50	2.75	0.84	0.93	3.61	0.71	1.36
Other Non-Cash Items	-0.01	-0.04	-0.04	-0.02	-0.01	-0.09	-0.04	–	–	–	–	–	–	–	–	–
Change in Accounts Receivable	-23	-3.02	-12	-9.10	-2.93	-2.34	-8.71	-5.18	-1.18	-6.17	-2.73	-8.14	0	-0.02	0.04	-0.04
Change in Inventory	-1.23	-4.29	2.90	-2.61	-4.03	-2.54	-3.26	0.24	-0.31	-2.11	-0.09	0.12	0	–	0.00	0.00
Change in Accounts Payable	2.97	-0.29	3.05	1.44	1.49	0.03	-1.02	0.90	-1.36	-1.08	1.73	2.77	-0.57	0.28	0.90	-0.05
Operating Cash Flow	52	58	35	18	29	18	-7.18	-0.41	-13	-20	-13	-25	-20	-30	-15	-14
Capital Expenditures	-27	-64	-20	-7.60	-7.92	-2.63	-2.62	-2.68	-1.51	-1.42	-2.43	-0.83	-0.04	-0.27	-0.12	-0.04
Acquisitions	–	–	–	–	–	–	–	–	–	0	0	-1.45	0	–	–	–
Purchase of Investments	-72	-68	-55	-70	-60	-63	-82	-67	0	0	–	–	–	–	-5.00	–
Sale & Maturity of Investments	56	53	80	41	64	49	–	–	–	–	–	–	–	–	–	–
Other Investing Activities	–	–	–	–	–	–	–	–	0	0	0.04	0.10	0	–	–	–
Investing Cash Flow	-44	-79	-3.13	-36	-3.50	-17	11	-67	-1.51	-1.42	-2.39	-2.18	-0.04	-0.27	-5.12	5.97
Stock Issued	14	25	6.00	–	–	–	–	–	–	–	–	–	–	–	–	–
Debt Repaid	–	–	–	–	–	0	0	-18	-7.15	-0.04	-0.04	-0.01	-0.03	-0.04	-0.48	-0.45
Taxes Paid on Share-Based Awards	-6.82	-5.46	-2.34	-1.49	-1.67	-0.16	0	–	–	–	–	–	–	–	–	–
Other Financing Activities	-0.05	0	-0.04	-0.04	-0.35	-0.03	-0.03	0	0	–	–	–	–	–	–	–
Financing Cash Flow	7.07	19	3.62	1.05	9.17	6.44	5.26	59	19	30	-0.02	50	14	38	17	8.35
Foreign Exchange Rate Adjustments	–	–	–	–	–	–	–	–	–	0	0	-0.05	0	–	–	–
Net Change in Cash	15	-1.82	36	-17	35	6.85	8.69	-8.58	3.88	–	–	–	–	–	–	–
Free Cash Flow	25	-5.81	15	10	21	15	-9.80	-3.09	-15	-21	-16	-26	-20	-30	-15	-14
Income Taxes Paid	0.58	0.63	1.17	0	0.38	0.15	0.08	0	0.10	0	0	–	–	–	–	–
Interest Paid	0.49	0.40	0.38	0.11	0.00	0.01	0.01	2.23	0.93	0.23	0	0	0.01	0.01	0.04	0.07

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 74.6%
Operating margin: 6.0%
Net margin: 7.9%
Return on equity, FY2025: 5.1%

Financial strength

Current ratio: 5.04
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 238.6%

Valuation

P/E ratio: 96.1
Price to sales: 6.89
Price to book: 5.71
Dividend yield: –